Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor

• Published in: Cancers Vol. 14; no. 6; p. 1478
• Main Authors: Siebenhüner, Alexander R, Langheinrich, Melanie, Friemel, Juliane, Schäfer, Niklaus, Eshmuminov, Dilmurodjon, Lehmann, Kuno
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14.03.2022; MDPI
• Subjects: Biomarkers; Biopsy; Clinical trials; Liver; Lymph nodes; Medical prognosis; Metastases; Metastasis; Neuroendocrine tumors; Pancreas; Patients; Review; Surgery; Veins & arteries; pancreatic; liver metastasis; timing; liver transplantation; neuroendocrine tumors; surgery
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14061478

Pancreatic neuroendocrine tumors (pNETs) are a vast growing disease. Over 50% of these tumors are recognized at advanced stages with lymph node, liver, or distant metastasis. An ongoing controversy is the role of surgery in the metastatic setting as dedicated systemic treatments have emerged recently and shown benefits in randomized trials. Today, liver surgery is an option for advanced pNETs if the tumor has a favorable prognosis, reflected by a low to moderate proliferation index (G1 and G2). Surgery in this well-selected population may prolong progression-free and overall survival. Optimal selection of a treatment plan for an individual patient should be considered in a multidisciplinary tumor board. However, while current guidelines offer a variety of modalities, there is so far only a limited focus on the right timing. Available data is based on small case series or retrospective analyses. The focus of this review is to highlight the right time-point for surgery in the setting of the multimodal treatment of an advanced pancreatic neuroendocrine tumor.